



Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 7 January 2022

Noxopharm Cash Position Strengthened with Receipt of a A\$5.865M Federal Government R&D Rebate

Sydney 7 January 2022: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to advise that it has received a \$5.865M cash refund under the Australian Government's Research and Development Tax Incentive Scheme for R&D expenditure during FY 2021.

The refund further strengthens the Company's cash position (\$23.6M on 30th September 2021) as it positions itself as an innovative partnering target.

Noxopharm CEO, Dr Graham Kelly, said, "The refunded cash is in line with our forecast and forms an important part of our forward budgeting activities, for which we thank the Government. The coming year holds a very significant level of activity and opportunity for the Company with our wide-ranging programs across cancer, septic shock, autoimmune disease and RNA drug/vaccine technology. It means we now go into a year of high growth in a healthy cash position."

-ENDS-

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).

Veyonda[®] is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda[®] has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING/TBK1 signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.



To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@atomicgroup.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.